
    
      A randomized clinical trial comparing administration convalescent plasma to standard therapy
      for severe COVID-19 disease. Patients will be randomized 1:1 in a single blind study. The
      patients with SARS-CoV-2 PCR confirmed infection with pulmonary infiltrates and hypoxemia
      will be screened and invited to participate. Our primary outcomes will be disease progression
      and mortality, evaluate of ordinal Scale for Clinical Improvement and. (WHO)
    
  